Tirzepatide
FDA approvedAlso known as: Mounjaro, Zepbound
The first dual incretin — superior to GLP-1 alone on weight, glucose, and metabolic markers.
Mechanism
GLP-1 / GIP dual agonist. The first dual incretin — superior to GLP-1 alone on weight, glucose, and metabolic markers. For full mechanism, dosing protocol, and stacking guidance, ask the AI Advisor or open the compound in-app.
Peer-Reviewed Studies (3)
Tirzepatide Once Weekly for Obesity (SURMOUNT-1)
22.5% mean weight loss at 72 weeks; 36.2% lost ≥25%.
PubMed PMID 35658024 →Tirzepatide vs Semaglutide in T2D (SURPASS-2)
Superior HbA1c reduction (-2.0% to -2.3%) and weight loss.
PubMed PMID 34170647 →Tirzepatide for HFpEF and Obesity (SUMMIT)
Improved HFpEF symptoms and exercise capacity.
PubMed PMID 39555827 →